Table 2.
Clinical characteristics of patients
| DLBCL (n = 13) | |
|---|---|
| Age | |
| Years, median (range) | 50 (25–61) |
| Sex | |
| Female | 5 (38.5) |
| Tumor burden | |
| LDH baseline | 275.5 (162–741) |
| Large tumor (>10 cm) | 4 (30.8) |
| TP53 mutation | 3 (23.1) |
| Tumor stage | |
| I–II | 0 (0.0) |
| II–IV | 13 (100.0) |
| “Double” and “triple” hit | |
| Yes | 3 (23.1) |
| No | 7 (53.8) |
| Undetermined | 3 (23.1) |
| Extranodal invasion | |
| Lymph node | 9 (45.0) |
| Skin | 2 (10.0) |
| Testis | 1 (5.0) |
| CNS | 2 (10.0) |
| Lung, stomach, adrenal glands, tongue, etc. | 6 (30.0) |
| Prior HSCT | |
| Autologous | 2(15.4) |
| Allogeneic | 1 (7.7) |
| Prior treatment | |
| First line | 3 (23.1) |
| Second line | 7 (53.8) |
| ≥Third line | 3 (23.1) |
| Refractory or relapsed | |
| Refractory | 3 (23.1) |
| First relapse | 7 (53.8) |
| ≥Second relapse | 3 (23.1) |
| CAR T cell dose, ×106 cells/kg, median (range) | |
| CAR19 T cells | 3.66 (11.6–4.08) |
| CAR22 T cells | 4.00 (2.00–4.86) |
| CRS grade | |
| 0–2 | 13 (100.0) |
| 3–5 | 0 (0.0) |
| Outcomes | |
| Response | 7 (53.8) |
| No response | 6 (46.2) |
| Follow-up time | |
| Days, median (range) | 725 (56–1677) |
CRS, cytokine release syndrome; LDH, lactate dehydrogenase.